The platform delivers high-throughput and high-quality binding data simultaneously, an intersection that historically required a trade-off between quantity and accuracy.
A growing proprietary database of hundreds of millions of measured interactions improves AlphaBind's predictive accuracy, and partnerships with large pharmaceutical companies demonstrate commercial demand.
The market for AI-driven drug discovery and proteomics tools is expanding as pharmaceutical companies seek faster target validation and lead optimization.
A-Alpha Bio is positioned to benefit from growth in biologics, molecular glues, and machine-learning-enabled protein engineering.
A-Alpha Bio's core products are AlphaSeq and AlphaBind. AlphaSeq is a synthetic-biology platform that uses yeast-based assays to quantify millions of protein-protein interactions in a single experiment.
AlphaBind applies machine learning to AlphaSeq data to predict binding affinity and optimize protein sequences for therapeutic and diagnostic applications.
